4D Molecular Therapeutics Q3 EPS $(1.01) Misses $(0.98) Estimate, Sales $90.000K Miss $287.857K Estimate
Benzinga Newsdesk 11 months ago
EarningsEarnings MissesNews
4D Molecular Therapeutics (NASDAQ:FDMT) reported quarterly losses of $(1.01) per share which missed the analyst consensus estimate of $(0.98) by 3.27 percent. This is a 27.85 percent decrease over losses of $(0.79) per
4D Molecular Therapeutics (NASDAQ:FDMT) reported quarterly losses of $(1.01) per share which missed the analyst consensus estimate of $(0.98) by 3.27 percent. This is a 27.85 percent decrease over losses of $(0.79) per share from the same period last year. The company reported quarterly sales of $90.000 thousand which missed the analyst consensus estimate of $287.857 thousand by 68.73 percent. This is a 2.90K percent increase over sales of $3.000 thousand the same period last year.